Abstract: Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.

Abstract: A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.

Abstract: This invention is directed to composites and films comprising hydroxyapatite, biodegradable polymer, a biocompatible surfactant with inorganic fullerene-like (IF) nanoparticles or inorganic nanotubes (INT); methods of preparation and uses thereof.

Abstract: The presently disclosed subject matter relates to the field of electrospun epoxy fibers, a solution for producing the fibers and a system for electrospinning the fibers. This invention further relates to processes of producing the solution and the fibers. By dissolving epoxy in a dielectric solvent, suitable electrospinning conditions are achieved by controlling the degree of epoxy crosslinking in the solution. The fibers are captured on a net screen, with the positive electrode placed behind it. The resulting electrospun fibers exhibit superior mechanical properties in comparison with other epoxy fibers. This improvement in mechanical properties is, in part, due to anisotropic molecular rearrangement resulting from the strong stretching forces induced by electrospinning.

Abstract: A quantum computing system comprises a plurality of photonic cavities, a plurality of coupling locations for quantum emitter positioning, a photon generator configured to supply photons to the plurality of photonic cavities, and a plurality of photon output channels downstream of the plurality of cavities to output a graph state. Each coupling location is associated with a differing one of the plurality of photonic cavities. Quantum emitters associated with each coupling location are configured to mediate interactions between consecutive incoming photonic qubits to generate the graph state, and the photonic cavities are configured to couple photonic qubits to the quantum emitters.

Abstract: A quantum computing system, method and computer readable storage medium involve tuning a whispering-gallery mode optical resonator to support a resonance frequency associated with a transition frequency of an atom. Operation of a laser is controlled to cause the atom to be trapped adjacent the optical resonator and within the evanescent field portion. Based on an atom presence signal from an optical atom presence detector, an indication is provided that the atom is trapped adjacent the optical resonator. A frequency of a cooling laser is controlled to cool the atom, and the optical resonator is configured to define a closed loop-like mode including an evanescent field portion. The trapping laser is configured to cause the atom to be trapped adjacent the whispering-gallery mode resonator, and the cooling laser is configured to manipulate a state of the atom to thereby cool the atom.

Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.

Abstract: This invention provides a catalytic process wherein alternating current is used for catalytic coupling (such as C—C, C—N, C—O, C—S, C—P, C—Si and/or C—B couplings) using a transition-metal catalysis.

Abstract: Provided herein are Sulfamate compounds for use in modulating an activity of peptidyl-prolyl isomerase NIMA-interacting-1 (Pin1).

Abstract: A quantum computing system includes a first silicon nitride resonator couplable to a first alkali atom, a second silicon resonator couplable to a second alkali atom, and a plurality of lasers for trapping, cooling, and manipulating the first alkali atom and the second alkali atom. Detectors detect a presence of the trapped first alkali atom and the trapped second alkali atom, and a processor is configured to receive at least one input signal from at least one of the detectors, the input signal indicating a presence of the trapped first alkali atom and the trapped second alkali atom, and, based on the received input, control at least some of the plurality of lasers to manipulate at least one of the trapped first alkali atom and the trapped second alkali atom to thereby generate photonic qubits using the trapped first alkali atom or generate entanglement between photonic qubits transmitted to the trapped second alkali atom.

Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.

Abstract: Methods and kits for diagnosing systemic lupus erythematosus (SLE) in a subject are provided. Particularly, the present invention relates to specific oligonucleotide antibody reactivities useful in diagnosing SLE in a subject.

Abstract: Methods of generating an isolated population of non-graft versus host disease (GVHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation, are disclosed. Cells generated by the methods, pharmaceutical compositions and methods of treatment are also disclosed.

Abstract: A multilayer optical element comprises a plurality of layers arranged along an optical axis, each layer having a plurality of nanostructures, wherein a size of—, and a spacing between—, the nanostructures is selected to provide a resonant response to an optical field at different wavelengths for different layers.

Abstract: Method for mapping the transverse relaxation times (T2) in a magnetic resonance imaging (MRI) scan defined over a plurality of pixels, where each pixel is associated with a multicomponent T2 (mcT2) signal, comprises: accessing a computer readable medium storing an mcT2 dictionary having a set of synthetic mcT2 signals, and selecting a subset of synthetic mcT2 signals for which correlations between the synthetic mcT2 signals and pixels in the MRI scan are highest among the set. For each of at least a portion of the pixels, a respective mcT2 scan signal is fitted to the subset to provide, a plurality of T2 values for the pixel. A T2 map of the MRI scan is generated based on the T2 values.

Abstract: A method of generating hematopoietic stem cells for transplantation is disclosed. The method comprising: (a) collecting hematopoietic stem cells; and (b) contacting the hematopoietic stem cells with an agent capable of decreasing an activity or expression of CD74 and/or of macrophage migration inhibitory factor (MIF), to thereby generate hematopoietic stem cells for transplantation, and wherein the hematopoietic stem cells are not transduced with a lentivirus. Methods of increasing mobilization of hematopoietic stem cells and methods of treatment are also provided.

Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.

Abstract: The present invention relates to novel manganese complexes and their use, inter alia, for homogeneous catalysis in (1) the preparation of imine by dehydrogenative coupling of an alcohol and amine; (2)C—C coupling in Michael addition reaction using nitriles as Michael donors; (3) dehydrogenative coupling of alcohols to give esters and hydrogen gas (4) hydrogenation of esters to form alcohols (including hydrogenation of cyclic esters (lactones) or cyclic di-esters (di-lactones), or polyesters); (5) hydrogenation of amides (including cyclic dipeptides, lactams, diamide, polypeptides and polyamides) to alcohols and amines (or diamine); (6) hydrogenation of organic carbonates (including polycarbonates) to alcohols or hydrogenation of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (7) dehydrogenation of secondary alcohols to ketones; (8) amidation of esters (i.e.

Abstract: The disclosure presented herein provides DNA constructs, recombinant cells comprising thereof, system comprising thereof, bacterial probes, and/or a recombinant cell decorated with various labels and/or synthetic agents, wherein said labels and/or synthetic agents can be reversibly modified or removed from the cells. Also disclosed herein are methods for decorating and/or modifying cells, preferably bacteria cells, and methods for using thereof.

Abstract: A method is disclosed for treating or preventing a myeloid malignancy in a subject harboring a mutation in SRSF2 comprising: (a) analyzing in a sample of the subject for the presence of an SRSF2 mutation; and (b) administering to the subject a therapeutically effective amount of a Rho Kinase inhibitor, or an inhibitor of a downstream effector thereof, upon identification of SRSF2 mutation.